<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    ImmunoGen, Inc.

    ImmunoGen, Inc.

    ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...

    ImmunoGen is developing the next generation of ...

    Filing Type:    PU
    Systec & Solutions GmbH

    Systec & Solutions GmbH

    Systec & Solutions GmbH, with headquarters in Karlsruhe (Germany), is a specialize...

    Systec & Solutions GmbH, with headquarters in K...

    Filing Type:    PR
    ViewRay, Inc.

    ViewRay, Inc.

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...

    Filing Type:    PU
    Inogen, Inc

    Inogen, Inc

    Inogen’s mission to improve the quality of life of supplemental oxygen users beg...

    Inogen’s mission to improve the quality of li...

    Filing Type:    PU
    Solid Biosciences Inc.

    Solid Biosciences Inc.

    Solid Biosciences is a life science company focused solely on finding meaningful t...

    Solid Biosciences is a life science company foc...

    Filing Type:    PU
    Bionik Laboratories Corp.

    Bionik Laboratories Corp.

    BIONIK is a global pioneering healthcare company on a mission to supply quality-of...

    BIONIK is a global pioneering healthcare compan...

    Filing Type:    PU
    Vir Biotechnology, Inc.

    Vir Biotechnology, Inc.

    Vir integrates diverse innovations in science, technology, and medicine to transfo...

    Vir integrates diverse innovations in science, ...

    Filing Type:    PU
    Celsion Corporation

    Celsion Corporation

    Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...

    Celsion Corporation is a fully integrated bioph...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Syndax Pharmaceuticals, Inc.

    Syndax Pharmaceuticals, Inc.

    Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on ...

    Syndax Pharmaceuticals, Inc. is a late-stage bi...

    Filing Type:    PU
    Halozyme Therapeutics, Inc.

    Halozyme Therapeutics, Inc.

    Halozyme is a clinical-stage biotechnology company focused on developing and comme...

    Halozyme is a clinical-stage biotechnology comp...

    Filing Type:    PU
    Adaptive Biotechnologies Corporation

    Adaptive Biotechnologies Corporation

    We are a commercial-stage biotech company focused on harnessing the inherent biolo...

    We are a commercial-stage biotech company focus...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.